JP2023526853A - ウイルス性呼吸器感染症の処置 - Google Patents

ウイルス性呼吸器感染症の処置 Download PDF

Info

Publication number
JP2023526853A
JP2023526853A JP2022571157A JP2022571157A JP2023526853A JP 2023526853 A JP2023526853 A JP 2023526853A JP 2022571157 A JP2022571157 A JP 2022571157A JP 2022571157 A JP2022571157 A JP 2022571157A JP 2023526853 A JP2023526853 A JP 2023526853A
Authority
JP
Japan
Prior art keywords
antagonist
subject
cells
antibody
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571157A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526853A5 (cg-RX-API-DMAC7.html
Inventor
ムハンマド タヒア ナッサー,サイード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosirius Ltd
Original Assignee
Biosirius Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosirius Ltd filed Critical Biosirius Ltd
Publication of JP2023526853A publication Critical patent/JP2023526853A/ja
Publication of JP2023526853A5 publication Critical patent/JP2023526853A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022571157A 2020-05-19 2021-05-19 ウイルス性呼吸器感染症の処置 Pending JP2023526853A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2007404.3A GB202007404D0 (en) 2020-05-19 2020-05-19 Treatment for viral respiratory infections
GB2007404.3 2020-05-19
PCT/GB2021/051207 WO2021234381A1 (en) 2020-05-19 2021-05-19 Treatment for viral respiratory infections

Publications (2)

Publication Number Publication Date
JP2023526853A true JP2023526853A (ja) 2023-06-23
JP2023526853A5 JP2023526853A5 (cg-RX-API-DMAC7.html) 2024-02-13

Family

ID=71135334

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571157A Pending JP2023526853A (ja) 2020-05-19 2021-05-19 ウイルス性呼吸器感染症の処置

Country Status (12)

Country Link
US (1) US20230192838A1 (cg-RX-API-DMAC7.html)
EP (1) EP4153302B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023526853A (cg-RX-API-DMAC7.html)
KR (1) KR20230053549A (cg-RX-API-DMAC7.html)
CN (1) CN116406289A (cg-RX-API-DMAC7.html)
AU (1) AU2021276614A1 (cg-RX-API-DMAC7.html)
CA (1) CA3179461A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982939T3 (cg-RX-API-DMAC7.html)
GB (1) GB202007404D0 (cg-RX-API-DMAC7.html)
HU (1) HUE067327T2 (cg-RX-API-DMAC7.html)
PL (1) PL4153302T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021234381A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230314432A1 (en) * 2020-07-10 2023-10-05 Covid Diagnostics Ltd. Compositions, methods, and systems for detecting immune response

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508511A (ja) * 2010-12-20 2014-04-10 メドイミューン・リミテッド 抗il−18抗体およびそれらの使用
JP2016536332A (ja) * 2013-09-05 2016-11-24 エイビー2 バイオ ソシエテアノニム 炎症性疾患におけるil−18結合タンパク質(il−18bp)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
AU2005327198B2 (en) 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
EP2112923A1 (en) 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
CN107660150B (zh) * 2015-03-05 2023-10-24 Ab2生物股份有限公司 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
EP4146174A1 (en) * 2020-05-06 2023-03-15 AB2 Bio SA Il-18 binding protein (il-18bp) in respiratory diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508511A (ja) * 2010-12-20 2014-04-10 メドイミューン・リミテッド 抗il−18抗体およびそれらの使用
JP2016536332A (ja) * 2013-09-05 2016-11-24 エイビー2 バイオ ソシエテアノニム 炎症性疾患におけるil−18結合タンパク質(il−18bp)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AUTOIMMUN. REV., vol. vol.19, issue 6, JPN6025009952, April 2020 (2020-04-01), pages 1 - 7, ISSN: 0005759922 *
IMMUNOLOGY, vol. vol.114, issue 1, JPN6025009951, 2005, pages 112 - 120, ISSN: 0005759921 *
LANCET, vol. vol.395, issue 10229, JPN6025009953, March 2020 (2020-03-01), pages 1054 - 1062, ISSN: 0005759923 *
POL. ARCH. INTERN. MED., vol. vol.130, issue 5, JPN6025009825, April 2020 (2020-04-01), pages 390 - 399, ISSN: 0005759924 *
順天堂医学, vol. 50, no. 2, JPN6025009954, 2004, pages 161 - 165, ISSN: 0005759925 *

Also Published As

Publication number Publication date
CN116406289A (zh) 2023-07-07
EP4153302A1 (en) 2023-03-29
US20230192838A1 (en) 2023-06-22
KR20230053549A (ko) 2023-04-21
AU2021276614A1 (en) 2023-01-05
GB202007404D0 (en) 2020-07-01
HUE067327T2 (hu) 2024-10-28
ES2982939T3 (es) 2024-10-21
WO2021234381A1 (en) 2021-11-25
EP4153302C0 (en) 2024-05-29
CA3179461A1 (en) 2021-11-25
PL4153302T3 (pl) 2024-10-07
EP4153302B1 (en) 2024-05-29

Similar Documents

Publication Publication Date Title
JP7609901B2 (ja) Il-4rアンタゴニストを投与することにより喘息を処置又は予防するための方法
Sokolowska et al. Immunology of COVID‐19: mechanisms, clinical outcome, diagnostics, and perspectives—a report of the European Academy of Allergy and Clinical Immunology (EAACI)
WO2021202563A1 (en) Methods of treating coronavirus infection
EP3703818B1 (en) Il-4r antagonist for use in a method for treating or preventing asthma
TWI857389B (zh) 治療發炎症狀的方法
JP2016536332A (ja) 炎症性疾患におけるil−18結合タンパク質(il−18bp)
EP4135837A1 (en) Methods for treating a complement mediated disorder caused by viruses
JP2018513116A (ja) 炎症性疾患におけるil−18結合タンパク質(il−18bp)および抗体
WO2020223704A1 (en) Anti-galectin-9 antibodies and uses thereof
CN112424226B (zh) 用于治疗重度哮喘的抗cd6抗体
BR112021003093A2 (pt) tratamento de câncer de mama triplo negativo que visa a inibição de tgf-beta
EP4153302B1 (en) Treatment for viral respiratory infections
WO2023067348A1 (en) Treatment for virally-induced pneumonia
JP2023518814A (ja) Covid-19肺炎における、il-6アンタゴニストに対する応答を予測するためのバイオマーカー
US20240117058A1 (en) Treatment of cytokine release syndrome with gm-csf antagonists
JPWO2003000286A1 (ja) 好酸球増多性疾患治療薬
US20230365712A1 (en) Notch4 antibodies and uses thereof
US20160355601A1 (en) Methods and Compositions for the Treatment of Pancreatic Cancer
US20230357418A1 (en) Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
US20230272087A1 (en) Method of treating or preventing acute respiratory distress syndrome
EP4107186A1 (en) Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
US20230416381A1 (en) Methods for treating or preventing acute respiratory distress syndrome
CN115916820A (zh) 用il6拮抗剂治疗包括covid-19肺炎在内的肺炎的方法
WO2021207667A1 (en) Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards)
KR20130110225A (ko) 인터페론을 사용하여 폐질환을 치료하는 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240202

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260423